Chronic obstructive pulmonary disease: fluticasone furoate, umeclidinium and vilanterol (Trelegy)
Chronic obstructive pulmonary disease: fluticasone furoate, umeclidinium and vilanterol (Trelegy) is the latest topic to be covered as part of our service to provide high quality medicines and prescribing information to the NHS and patients in England.
Evidence summaries provide a summary of the best available evidence for selected medicines that are considered to be of significance to the NHS. These medicines include new medicines, existing medicines with new indications or formulations, off-label use of licensed medicines and unlicensed medicines. The summaries aim to support decision-making, nationally within NHS England and locally, for example within a clinical commissioning group, an NHS trust, or across a local health economy. The evidence summaries do not include recommendations and do not constitute formal NICE guidance.
Information about the process used to develop them and those evidence summaries that are currently being developed is available on the NICE website.
|